KETOTIFEN PILLS 1 MG

Packaging

In a blister pack of 10 tablets. In a cardboard bundle 3 packs.

Mechanism of action

Ketotifen - a stabilizer of mast cell membranes, has moderate H 1 -histamino blocking activity, inhibits the release of histamine, leukotrienes from basophils and neutrophils, reduces the accumulation of eosinophils in the respiratory tract and the reaction to histamine, suppresses early and late asthmatic reactions to the allergen.

Prevents the development of bronchospasm, does not have a bronchodilating effect.

Inhibits phosphodiesterase, resulting in an increased content of cAMP in the cells of adipose tissue.

The therapeutic effect is fully manifested in 1.5-2 months. from the start of therapy.

Indications and usage

- Atopic bronchial asthma.
- Hay fever (hay fever).
- Allergic rhinitis.
- Allergic conjunctivitis.
- Atopic dermatitis.
- Urticaria.

Contraindications

- Hypersensitivity.
- Pregnancy.
- Lactation period.
- Children's age up to 1 year.

With caution:

- Epilepsy.
- Liver failure.

Pregnancy and Breastfeeding

Contraindicated use during pregnancy and breastfeeding.

Dosage and administration

Inside, while eating.

Adults - 1 mg 2 times a day, morning and evening. If necessary, increase the dose to 2 mg 2 times a day.
Children: from 1 year to 3 years - 0.5 mg 2 times a day; from 3 years and older - 1 mg 2 times a day.

The duration of treatment is at least 3 months.

The abolition of therapy is carried out gradually, within 2-4 weeks.

Adverse reactions

Nervous system: drowsiness, dizziness, slowing down of the reaction rate (disappear after a few days of therapy), sedation, fatigue; rarely - anxiety, sleep disturbances, nervousness (especially in children).

Gastrointestinal: dry mouth, increased appetite, nausea, vomiting, gastralgia, constipation.

On the part of urination: dysuria, cystitis.

Other: thrombocytopenia, weight gain, allergic skin reactions.

Special notes

The abrupt cancellation of the previous treatment with beta-adrenostimulants, glucocorticosteroids, ACTH in patients with bronchial asthma and bronchospastic syndrome after joining Ketotifen therapy is undesirable, and the withdrawal is carried out for at least 2 weeks, gradually reducing the dose.

Treatment is stopped gradually, within 2-4 weeks (possible recurrence of asthmatic symptoms).

Persons sensitive to sedative action, in the first 2 weeks, the drug is prescribed in small doses.

Not intended for the relief of an asthma attack.

In patients receiving oral hypoglycemic agents at the same time, the number of platelets in the peripheral blood should be monitored.

During the period of treatment, it is necessary to refrain from driving vehicles and practicing potentially hazardous activities that require increased concentration and psychomotor speed.

Drug interactions

Enhances the effect of sleeping pills, antihistamines, ethanol.

In combination with hypoglycemic drugs increases the likelihood of thrombocytopenia.

Overdosage

Symptoms: drowsiness, confusion, disorientation, brady- or tachycardia, lowering blood pressure, shortness of breath, cyanosis, convulsions, irritability, coma.
Treatment: gastric lavage (if a little time has passed since the moment of admission), symptomatic treatment, with the development of convulsive syndrome - barbiturates or benzodiazepines. Dialysis is ineffective.

Store in a dry, dark place at a temperature not exceeding 25 ° C.

3 years

Ketotifen